Bajaj Healthcare acquires Genrx Pharma for Rs 10.85 crore
Mumbai: Bajaj Healthcare Limited has announced the successful acquisition of Genrx Pharmaceuticals Private Limited (in Liquidation) as a going concern, as per the Sale Certificate dated April 4, 2025, issued by the Official Liquidator.
The acquisition, valued at Rs 10.85 crore through a cash consideration, involves 100% control of the target entity.
Incorporated in 2009 and headquartered in Thane, Maharashtra, GenRx Pharmaceuticals Private Limited is a WHO-GMP certified pharmaceutical manufacturer engaged in the production of allopathic formulations, nutraceuticals, and natural products. The company operates a manufacturing facility located at MIDC Sinnar, Nashik, with the capability to produce solid and semi-solid dosage forms such as tablets, capsules, external preparations, cosmetic products, and nasal sprays.
Speaking at the occasion Anil Jain, Managing Director, Bajaj Healthcare Limited, said, “The acquisition of Genrx Pharmaceuticals marks a strategic step forward in expanding our formulations manufacturing capabilities. This aligns with our vision of strengthening our core business and leveraging synergies for accelerated growth. Completion of the acquisition is expected within 3–6 months, subject to requisite FDA and other regulatory approvals. This addition will enable us to expand our manufacturing portfolio, paving the way for long-term value creation and strengthening our footprint in the pharmaceutical sector.”
Medical Dialogues team had earlier reported that the Company had received a recommendation from the Subject Expert Committee (SEC) (Neurology & Psychiatry) of the Central Drugs Standard Control Organisation (CDSCO) to conduct Phase III clinical trials for Cenobamate Tablets in strengths of 12.5mg, 25mg, 50mg, 100mg, 150mg, and 200mg.
Read also: Bajaj Healthcare gets CDSCO panel nod for Phase III trials for anti-seizure drug
Established in the year 1993, Bajaj Healthcare Limited is a Manufacturer of APIs, Intermediates and Formulations. It specializes in manufacturing of intermediates, API, formulations & Nutraceuticals. The Company has state-of-art manufacturing facilities of APIs, intermediates and formulations. Bajaj has a strong presence globally in countries like Europe, USA, Australia, Middle East and South America.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.